Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

Observed annually on March 10, National Women and Girls HIV/AIDS Awareness Day (NWGHAAD) 2025 serves as a crucial reminder of ...

Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, saying they are "doing catastrophic harm" to the global fight against AIDS.